Impact of Elotuzumab Plus Pomalidomide/Dexamethasone on Health-related Quality of Life for Patients with Relapsed/Refractory Multiple Myeloma: Final Data from the Phase 2 ELOQUENT-3 Trial

  1. Weisel, K.
  2. Dimopoulos, M.A.
  3. San-Miguel, J.
  4. Paner, A.
  5. Engelhardt, M.
  6. Taylor, F.
  7. Lord-Bessen, J.
  8. Yip, C.
  9. Greenwood, M.
  10. Tang, J.
  11. Cavo, M.
Zeitschrift:
HemaSphere

ISSN: 2572-9241

Datum der Publikation: 2023

Ausgabe: 7

Nummer: 3

Seiten: E843

Art: Artikel

DOI: 10.1097/HS9.0000000000000843 GOOGLE SCHOLAR lock_openOpen Access editor
Datenquelle: Scopus